Plus Therapeutics(PSTV) - 2025 Q3 - Quarterly Results
Plus Therapeutics(US:PSTV)2025-10-30 20:15US market introduction of the CNSide® CSF diagnostics platform, with first national coverage agreement with UnitedHealthcare Presented positive RESPECT-LM Ph1 clinical trial results HOUSTON, Texas, October 30, 2025 (GLOBE NEWSWIRE) – Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the third quarter ...